The Confluence of Stereotactic Ablative Radiotherapy and Tumor Immunology
Stereotactic radiation approaches are gaining more popularity for the treatment of intracranial as well as extracranial tumors in organs such as the liver and lung. Technology, rather than biology, is driving the rapid adoption of stereotactic body radiation therapy (SBRT), also known as stereotacti...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2011/439752 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832559393609089024 |
|---|---|
| author | Steven Eric Finkelstein Robert Timmerman William H. McBride Dörthe Schaue Sarah E. Hoffe Constantine A. Mantz George D. Wilson |
| author_facet | Steven Eric Finkelstein Robert Timmerman William H. McBride Dörthe Schaue Sarah E. Hoffe Constantine A. Mantz George D. Wilson |
| author_sort | Steven Eric Finkelstein |
| collection | DOAJ |
| description | Stereotactic radiation approaches are gaining more popularity for the treatment of intracranial as well as extracranial tumors in organs such as the liver and lung. Technology, rather than biology, is driving the rapid adoption of stereotactic body radiation therapy (SBRT), also known as stereotactic ablative radiotherapy (SABR), in the clinic due to advances in precise positioning and targeting. Dramatic improvements in tumor control have been demonstrated; however, our knowledge of normal tissue biology response mechanisms to large fraction sizes is lacking. Herein, we will discuss how SABR can induce cellular expression of MHC I, adhesion molecules, costimulatory molecules, heat shock proteins, inflammatory mediators, immunomodulatory cytokines, and death receptors to enhance antitumor immune responses. |
| format | Article |
| id | doaj-art-047ef16552d34d5ea77fbbed8a98ec88 |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-047ef16552d34d5ea77fbbed8a98ec882025-02-03T01:30:00ZengWileyClinical and Developmental Immunology1740-25221740-25302011-01-01201110.1155/2011/439752439752The Confluence of Stereotactic Ablative Radiotherapy and Tumor ImmunologySteven Eric Finkelstein0Robert Timmerman1William H. McBride2Dörthe Schaue3Sarah E. Hoffe4Constantine A. Mantz5George D. Wilson621st Century Oncology Translational Research Consortium, Scottsdale, AZ 85251, USADepartment of Radiation Oncology and Neurologic Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75391, USADepartment of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USADepartment of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USADepartment of Radiation Oncology, Moffitt International, Tampa, FL 33612, USA21st Century Oncology Translational Research Consortium, Scottsdale, AZ 85251, USADivision of Radiation Biology, William Beaumont Hospital, Royal Oak, MI 48073, USAStereotactic radiation approaches are gaining more popularity for the treatment of intracranial as well as extracranial tumors in organs such as the liver and lung. Technology, rather than biology, is driving the rapid adoption of stereotactic body radiation therapy (SBRT), also known as stereotactic ablative radiotherapy (SABR), in the clinic due to advances in precise positioning and targeting. Dramatic improvements in tumor control have been demonstrated; however, our knowledge of normal tissue biology response mechanisms to large fraction sizes is lacking. Herein, we will discuss how SABR can induce cellular expression of MHC I, adhesion molecules, costimulatory molecules, heat shock proteins, inflammatory mediators, immunomodulatory cytokines, and death receptors to enhance antitumor immune responses.http://dx.doi.org/10.1155/2011/439752 |
| spellingShingle | Steven Eric Finkelstein Robert Timmerman William H. McBride Dörthe Schaue Sarah E. Hoffe Constantine A. Mantz George D. Wilson The Confluence of Stereotactic Ablative Radiotherapy and Tumor Immunology Clinical and Developmental Immunology |
| title | The Confluence of Stereotactic Ablative Radiotherapy and Tumor Immunology |
| title_full | The Confluence of Stereotactic Ablative Radiotherapy and Tumor Immunology |
| title_fullStr | The Confluence of Stereotactic Ablative Radiotherapy and Tumor Immunology |
| title_full_unstemmed | The Confluence of Stereotactic Ablative Radiotherapy and Tumor Immunology |
| title_short | The Confluence of Stereotactic Ablative Radiotherapy and Tumor Immunology |
| title_sort | confluence of stereotactic ablative radiotherapy and tumor immunology |
| url | http://dx.doi.org/10.1155/2011/439752 |
| work_keys_str_mv | AT stevenericfinkelstein theconfluenceofstereotacticablativeradiotherapyandtumorimmunology AT roberttimmerman theconfluenceofstereotacticablativeradiotherapyandtumorimmunology AT williamhmcbride theconfluenceofstereotacticablativeradiotherapyandtumorimmunology AT dortheschaue theconfluenceofstereotacticablativeradiotherapyandtumorimmunology AT sarahehoffe theconfluenceofstereotacticablativeradiotherapyandtumorimmunology AT constantineamantz theconfluenceofstereotacticablativeradiotherapyandtumorimmunology AT georgedwilson theconfluenceofstereotacticablativeradiotherapyandtumorimmunology AT stevenericfinkelstein confluenceofstereotacticablativeradiotherapyandtumorimmunology AT roberttimmerman confluenceofstereotacticablativeradiotherapyandtumorimmunology AT williamhmcbride confluenceofstereotacticablativeradiotherapyandtumorimmunology AT dortheschaue confluenceofstereotacticablativeradiotherapyandtumorimmunology AT sarahehoffe confluenceofstereotacticablativeradiotherapyandtumorimmunology AT constantineamantz confluenceofstereotacticablativeradiotherapyandtumorimmunology AT georgedwilson confluenceofstereotacticablativeradiotherapyandtumorimmunology |